Good Results for Novo Nordisk
Bagsvaerd - Danish Novo Nordisk A/S announced the first results from a large clinical trial conducted with a pharmaceutical agent in the treatment of intracerebral hemorrhage (ICH) in late June. The phase-2b study demonstrated that treatment with NovoSeven® of ICH patients led to a significant reduction in hematoma growth compared to the placebo group.
Earlier this month the European Commission had granted marketing authorization for the company's new, long-acting insulin analogue Levemir® for the treatment of diabetes. Novo Nordisk will launch Levemir first in the UK and in other European markets in the second half of 2004.